Kornitzer Capital Management Inc. KS Trims Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Kornitzer Capital Management Inc. KS lowered its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 3.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 205,649 shares of the biopharmaceutical company's stock after selling 7,550 shares during the quarter. Kornitzer Capital Management Inc. KS owned about 0.17% of Halozyme Therapeutics worth $13,122,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Penserra Capital Management LLC acquired a new position in shares of Halozyme Therapeutics in the 1st quarter worth approximately $125,000. Bessemer Group Inc. lifted its stake in Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 207 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its position in shares of Halozyme Therapeutics by 171.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after buying an additional 524,802 shares during the period. Fifth Third Bancorp grew its stake in shares of Halozyme Therapeutics by 29.4% in the first quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock valued at $639,000 after buying an additional 2,276 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Halozyme Therapeutics by 199.0% in the 1st quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock valued at $179,000 after buying an additional 1,865 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on HALO. HC Wainwright reaffirmed a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. JPMorgan Chase & Co. raised their price objective on shares of Halozyme Therapeutics from $58.00 to $60.00 and gave the company a "neutral" rating in a research note on Wednesday. Leerink Partners downgraded shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a research note on Tuesday, May 13th. Morgan Stanley lowered shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and reduced their target price for the stock from $73.00 to $62.00 in a report on Wednesday, May 14th. Finally, The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price target for the company. Two analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $62.70.

Halozyme Therapeutics Stock Down 0.3%

Shares of HALO traded down $0.20 during midday trading on Thursday, reaching $57.81. The stock had a trading volume of 1,110,490 shares, compared to its average volume of 1,750,384. The company has a market cap of $7.12 billion, a price-to-earnings ratio of 15.38, a PEG ratio of 0.38 and a beta of 1.15. The company's fifty day simple moving average is $54.68 and its two-hundred day simple moving average is $57.08. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $70.51. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. The company had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. Halozyme Therapeutics's revenue for the quarter was up 35.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.79 EPS. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of the company's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the completion of the transaction, the director owned 28,611 shares in the company, valued at $1,727,246.07. This represents a 13.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total value of $1,128,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $41,403,763.17. The trade was a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold 64,497 shares of company stock worth $3,533,884 over the last quarter. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.